Myeloma
At #EHA2025, Dr Shaji Kumar presented encouraging results from a phase II trial of teclistamab and talquetamab in extramedullary multiple myeloma. The bispecific combination achieved an 80% response rate and 55% complete responses, offering a promising new option for this aggressive, high-risk disease with limited treatment success to date.
At #EHA2025, Dr Gurbaksh Kaur presented updated results from the iMMagine-1 trial of AnitoCell, a BCMA-targeted CAR T therapy. With a 97% response rate and manageable safety, the D-domain construct shows early promise in relapsed/refractory myeloma. Kaur discusses efficacy, neurotoxicity, sequencing questions and where the field is headed next.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
Dr. Miguel-Angel Perales discusses the need to expand access to CAR T-cell therapy by increasing awareness among community physicians. Real-world data show comparable or improved outcomes compared to trials, even in older and sicker patients, underscoring the importance of timely referrals for this innovative cancer treatment.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Nurses account for the largest group of professionals in the healthcare system and there are an estimated 29 million nurses worldwide (WHO, 2024). Nursing practice needs to be dynamic in order to respond to the changing needs of an aging population and ...
With the the 66th ASH Annual Meeting & Exposition still fresh in our minds, Dr Rahul Banerjee (Fred Hutch Cancer Center, Seattle, WA, USA) and Dr Samer Al Hadidi (University of Arkansas for Medical Sciences, Little Rock, AR, USA) outline ...
Isatuximab is a CD38-receptor targeted monoclonal antibody approved as a combination therapy for the treatment of RRMM in patients who have received 1 to 3 lines of prior therapy.
The phase III DREAMM-7 trial evaluated the efficacy and safety of belantamab mafodotin plus bortezomib and dexamethasone (BVd) compared to daratumumab plus bortezomib and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM) patients with ≥1 prior therapy. Involving 494 patients, the study found that BVd significantly improved progression-free survival (PFS) (36.6 months versus 13.4 months) and showed a strong trend towards improved overall survival (OS). BVd also resulted in a higher overall response rate (82.7% versus 71.3%) and longer median duration of response (35.6 months versus 17.8 months). Grade 3/4 adverse events were higher in the BVd group (90% versus 67%), including more frequent but manageable ocular events. These results support BVd as a potential new standard of care for RRMM.
touchHAEMATOLOGY coverage of data presented at EHA 2024: The phase I/II CAMMA 2 study evaluates cevostamab, a bispecific antibody targeting FcRH5xCD3, in patients with relapsed/refractory multiple myeloma (RRMM) who are triple-class refractory and have received prior B-cell maturation antigen (...
The 29th European Hematology Association (EHA) 2024 Congress was held on 13–16th June 2024 in Madrid, Spain. As with every year, the EHA Congress covered a wide array of topics in haematology and haematological malignancies. Key data presented at the congress not only highlighted significant advancements in these areas but also provided insights that could shape future clinical practices.
We delve into the exploratory analysis of the DETERMINATION study data, which suggests a potential meaningful progression-free survival (PFS) benefit for African American (AA) patients receiving RVd-alone treatment. We also examine safety findings, noting a similar safety profile between AA and White patients, despite the high prevalence of Duffy-null alleles in AA patients. However, we observe that neuropathic toxicity may be higher in AA patients. Finally, we discuss how these clinical insights could influence treatment decisions for newly diagnosed multiple myeloma patients
The EHA 2024 congress has once again united top haematology experts from around the globe. This year's event featured plenty of innovations and developments, from novel therapies to cutting-edge genetic studies. In this article we provide an overview of the late-breaking abstracts presented at the meeting.
We’re looking forward to the EHA 2024 Hybrid Congress which is taking place in Madrid, between 13-16 June 2024. Promising attendees the opportunity to explore the latest advancements in haematology, including cutting-edge technologies, treatments, and products. The focus will encompass a ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
